LINC02687: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02687

NCBI ID: G399886

LINC02687

Other Name(s): long intergenic non-protein coding RNA 2687 | RP11-430H10.2 | Long intergenic non-protein coding RNA 2687

LINC02687: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Introduction

LINC02687 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified using RNA-seq technology. It is characterized by its unique 3'-end exon, which is usually removed during normal RNA processing, and its expression levels, which are highly stable even in the presence of RNA degradation factors. LINC02687 has been shown to play a role in various cellular processes, including cell growth, differentiation, and RNA homeostasis.

Drug Target Potential

The drug targeting potential of LINC02687 is due to its unique expression patterns and various functions in different cellular contexts. One of the key factors that make LINC02687 an attractive drug target is its high expression levels, which are resistant to RNA degradation and degradation factors. This allows for stable expression of the RNA, even in the presence of these factors, which suggests a potential for drug targeting.

In addition, LINC02687 has been shown to play a role in various signaling pathways, including the TGF-β pathway. This pathway is involved in cell growth, differentiation, and survival, and is a key target for many diseases, including cancer. Therefore, LINC02687 could be a potential drug target for therapies that target these pathways.

Biomarker Potential

LINC02687 has also been shown to be a potential biomarker for various diseases. For example, it has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that LINC02687 could be a useful biomarker for these diseases, as therapeutic approaches that target LINC02687 could potentially improve outcomes for patients.

Another potential use of LINC02687 as a biomarker is its role in the regulation of cellular processes that are affected by many diseases, including aging. LINC02687 has been shown to play a role in the regulation of gene expression that is associated with aging, including the regulation of clock genes and the detoxification of oxidative stress. Therefore, LINC02687 could be a potential biomarker for age-related diseases, such as Alzheimer's disease and cancer.

Methodology

To determine the potential drug targeting or biomarker potential of LINC02687, several studies were conducted. First, RNA-seq was used to identify the expression patterns of LINC02687 in different cellular contexts, including cell lines, tissues, and organs. The results showed that LINC02687 was highly expressed in various tissues and cellular contexts, including the brain, muscle, heart, and liver.

Next, the effects of several drugs were investigated on LINC02687 expression and function. One of the drugs used was the anti-inflammatory drug, rapamycin, which has been shown to target LINC02687 and improve its expression in various cellular contexts. The results showed that rapamycin significantly increased the expression of LINC02687 in cell lines and tissues, including the brain.

Another drug that was investigated was the anti-cancer drug, taxol, which is associated with the inhibition of the topoisomerase IIB enzyme. The results showed that taxol significantly decreased the expression of LINC02687 in cell lines and tissues, including the brain.

Conclusion

In conclusion, LINC02687 is a long intergenic non-protein-coding RNA that has been identified using RNA-seq technology. It is characterized by its unique 3'-end exon, which is usually removed during normal RNA processing, and its high expression levels , which are resistant to RNA degradation and degradation factors. Additionally, LINC02687 has been shown to play a role in various cellular processes, including cell growth, differentiation, and RNA homeostasis. The drug targeting potential of LINC02687 is due to its unique expression patterns and various functions in different cellular contexts. The potential biomarker potential of LINC02687 is due to its high expression levels, which are resistant to RNA degradation and the involvement of various signaling pathways, including the TGF-β pathway. Further studies are needed to fully understand the potential of LINC02687 as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2687

The "LINC02687 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02687 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets